Retatrutide, developed by Soma Pharmaceuticals , is receiving increasing attention as a potential method for obesity management . This unique drug integrates the activity of a GLP-1 receptor agonist and a GIP receptor activator , intended to not only promote metabolic improvements but also improve related metabolic factors. Initial human data have